{
    "Clinical Trial ID": "NCT00038103",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Exemestane (Exemestane Alone)",
        "  oral dose exemestane taken with food (25 mg tablet once daily)",
        "INTERVENTION 2: ",
        "  Combination (Exemestane + Celecoxib)",
        "  oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Postmenopausal female patient with histologically or cytologically confirmed breast cancer having progressed on Tamoxifen.",
        "  Advanced disease: patients with advanced breast carcinoma with disease progression who had progressed/relapsed following > 8 weeks of treatment with Tamoxifen for advanced disease; or progressed during adjuvant Tamoxifen for at least 6 or 12 months depending on receptor status; or progressed within 12 months from completion of adjuvant treatment with Tamoxifen.",
        "  at least one measurable lesion",
        "Exclusion Criteria:",
        "  More than one previous chemotherapy and/or more than one hormonotherapy for advanced disease.",
        "  Previous hormonotherapy for advanced disease other than Tamoxifen.",
        "  Myocardial infarction within previous 6 mo"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Number of Subjects With Clinical Benefit",
        "  Clinical benefit was based on objective tumor assessments made according to Response Evaluation Criteria (RECIST) system of unidimensional evaluation. Includes subjects with complete response (CR), partial response (PR), and long term disease stabilization (SD) for at least 24 weeks.",
        "  Time frame: Baseline, Week 8, 16, 24, and every 12 weeks beyond 24 up to Week 108 and every 24 weeks thereafter until 9 months following last subject last visit (LSLV)",
        "Results 1: ",
        "  Arm/Group Title: Exemestane (Exemestane Alone)",
        "  Arm/Group Description: oral dose exemestane taken with food (25 mg tablet once daily)",
        "  Overall Number of Participants Analyzed: 49",
        "  Measure Type: Number",
        "  Unit of Measure: participants  24",
        "Results 2: ",
        "  Arm/Group Title: Combination (Exemestane + Celecoxib)",
        "  Arm/Group Description: oral doses to be taken with food (25 mg tablet exemestane once daily; celecoxib 2 x 200 mg tablets twice daily)",
        "  Overall Number of Participants Analyzed: 51",
        "  Measure Type: Number",
        "  Unit of Measure: participants  24"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 9",
        "  Cardiac Failure Congestive  0/53 (0.00%)",
        "  Ascites  1/53 (1.89%)",
        "  Nausea  1/53 (1.89%)",
        "  Vomiting  2/53 (3.77%)",
        "  Intestinal Obstruction  1/53 (1.89%)",
        "  Diarrhoea  0/53 (0.00%)",
        "  Pain  1/53 (1.89%)",
        "  Death  1/53 (1.89%)",
        "  General physical health deterioration  1/53 (1.89%)",
        "  Gait Disturbance  1/53 (1.89%)",
        "  Asthenia  2/53 (3.77%)",
        "  Fatigue  0/53 (0.00%)",
        "Adverse Events 2:",
        "  Total: 14",
        "  Cardiac Failure Congestive  1/56 (1.79%)",
        "  Ascites  0/56 (0.00%)",
        "  Nausea  0/56 (0.00%)",
        "  Vomiting  0/56 (0.00%)",
        "  Intestinal Obstruction  0/56 (0.00%)",
        "  Diarrhoea  1/56 (1.79%)",
        "  Pain  1/56 (1.79%)",
        "  Death  1/56 (1.79%)",
        "  General physical health deterioration  1/56 (1.79%)",
        "  Gait Disturbance  1/56 (1.79%)",
        "  Asthenia  0/56 (0.00%)",
        "  Fatigue  1/56 (1.79%)"
    ]
}